The primary risk factor for atherosclerotic cardiovascular disease is LDL cholesterol, which can be reduced by increasing cholesterol excretion from the body. Fecal cholesterol excretion can be driven by a hepatobiliary as well as a non-biliary pathway known as transintestinal cholesterol efflux (TICE). We previously showed that chronic knockdown of the hepatic cholesterol esterifying enzyme sterol O-acyltransferase 2 (SOAT2) increased fecal cholesterol loss via TICE. To elucidate the initial events that stimulate TICE, C57Bl/6 mice were fed a high cholesterol diet to induce hepatic cholesterol accumulation and were then treated for 1 or 2 weeks with an antisense oligonucleotide targeting SOAT2. Within 2 weeks of hepatic SOAT2 knockdown (SOAT2HKD), the concentration of cholesteryl ester in the liver was reduced by 70% without a reciprocal increase in hepatic free cholesterol. The rapid mobilization of hepatic cholesterol stores resulted in a ~2-fold increase in fecal neutral sterol loss but no change in biliary cholesterol concentration. Acute SOAT2HKD increased plasma cholesterol carried primarily in lipoproteins enriched in apoB and apoE. Collectively, our data suggest that acutely reducing SOAT2 causes hepatic cholesterol to be swiftly mobilized and packaged onto nascent lipoproteins that feed cholesterol into the TICE pathway for fecal excretion.
References
[1]
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127: e6–e245. doi: 10.1161/cir.0b013e31828124ad
[2]
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM J, et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207. doi: 10.1056/nejmoa0807646
[3]
Besseling J, van Capelleveen J, Kastelein JJ, Hovingh GK (2013) LDL cholesterol goals in high-risk patients: how low do we go and how do we get there? Drugs 73: 293–301. doi: 10.1007/s40265-013-0028-0
Chang TY, Chang CC, Cheng D (1997) Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem 66: 613–638. doi: 10.1146/annurev.biochem.66.1.613
[6]
Rudel LL, Lee RG, Parini P (2005) ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 25: 1112–1118. doi: 10.1161/01.atv.0000166548.65753.1e
[7]
Temel RE, Hou L, Rudel LL, Shelness GS (2007) ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins. J Lipid Res 48: 1618–1627. doi: 10.1194/jlr.m700109-jlr200
[8]
Temel RE, Lee RG, Kelley KL, Davis MA, Shah R, et al. (2005) Intestinal cholesterol absorption is substantially reduced in mice deficient in both ABCA1 and ACAT2. J Lipid Res 46: 2423–2431. doi: 10.1194/jlr.m500232-jlr200
Zhang J, Kelley KL, Marshall SM, Davis MA, Wilson MD, et al. (2012) Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. J Lipid Res 53: 1144–1152. doi: 10.1194/jlr.m024356
[11]
Nguyen TM, Sawyer JK, Kelley KL, Davis MA, Rudel LL (2012) Cholesterol esterification by ACAT2 is essential for efficient intestinal cholesterol absorption: evidence from thoracic lymph duct cannulation. J Lipid Res 53: 95–104. doi: 10.1194/jlr.m018820
[12]
Lee RG, Shah R, Sawyer JK, Hamilton RL, Parks JS, et al. (2005) ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res 46: 1205–1212. doi: 10.1194/jlr.m500018-jlr200
[13]
Melchior JT, Sawyer JK, Kelley KL, Shah R, Wilson MD, et al. (2013) LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis. J Lipid Res 54: 2495–2503. doi: 10.1194/jlr.m039644
[14]
Lee RG, Kelley KL, Sawyer JK, Farese RV Jr, Parks JS, et al. (2004) Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res 95: 998–1004. doi: 10.1161/01.res.0000147558.15554.67
[15]
Willner EL, Tow B, Buhman KK, Wilson M, Sanan DA, et al. (2003) Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 100: 1262–1267. doi: 10.1073/pnas.0336398100
[16]
Buhman KK, Accad M, Novak S, Choi RS, Wong JS, et al. (2000) Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med 6: 1341–1347.
[17]
Bell TA 3rd, Kelley K, Wilson MD, Sawyer JK, Rudel LL (2007) Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice. Arterioscler Thromb Vasc Biol 27: 1396–1402. doi: 10.1161/atvbaha.107.142802
[18]
Furbee JW Jr, Francone O, Parks JS (2002) In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice. J Lipid Res 43: 428–437.
[19]
Ohshiro T, Matsuda D, Sakai K, Degirolamo C, Yagyu H, et al. (2011) Pyripyropene A, an acyl-coenzyme A:cholesterol acyltransferase 2-selective inhibitor, attenuates hypercholesterolemia and atherosclerosis in murine models of hyperlipidemia. Arterioscler Thromb Vasc Biol 31: 1108–1115. doi: 10.1161/atvbaha.111.223552
[20]
Bell TA 3rd, Brown JM, Graham MJ, Lemonidis KM, Crooke RM, et al. (2006) Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 26: 1814–1820. doi: 10.1161/01.atv.0000225289.30767.06
[21]
Brown JM, Bell TA 3rd, Alger HM, Sawyer JK, Smith TL, et al. (2008) Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J Biol Chem 283: 10522–10534. doi: 10.1074/jbc.m707659200
[22]
Temel RE, Brown JM (2012) Biliary and nonbiliary contributions to reverse cholesterol transport. Curr Opin Lipidol 23: 85–90. doi: 10.1097/mol.0b013e3283508c21
[23]
Brufau G, Groen AK, Kuipers F (2011) Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol 31: 1726–1733. doi: 10.1161/atvbaha.108.181206
[24]
Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, et al. (2010) Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem 285: 14267–14274. doi: 10.1074/jbc.m110.118422
[25]
Parini P, Davis M, Lada AT, Erickson SK, Wright TL, et al. (2004) ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation 110: 2017–2023. doi: 10.1161/01.cir.0000143163.76212.0b
[26]
Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, et al. (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478: 404–407. doi: 10.1038/nature10486
[27]
Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917.
[28]
Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, et al. (2007) Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117: 1968–1978. doi: 10.1172/jci30060
[29]
Carr TP, Andresen CJ, Rudel LL (1993) Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 26: 39–42. doi: 10.1016/0009-9120(93)90015-x
[30]
Temel RE, Sawyer JK, Yu L, Lord C, Degirolamo C, et al. (2010) Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab 12: 96–102. doi: 10.1016/j.cmet.2010.05.011
[31]
Wei E, Ben Ali Y, Lyon J, Wang H, Nelson R, et al. (2010) Loss of TGH/Ces3 in Mice Decreases Blood Lipids, Improves Glucose Tolerance, and Increases Energy Expenditure. Cell Metab 11: 183–193. doi: 10.1016/j.cmet.2010.02.005
[32]
Gilham D, Lehner R (2004) The physiological role of triacylglycerol hydrolase in lipid metabolism. Rev Endocr Metab Disord 5: 303–309. doi: 10.1023/b:remd.0000045101.42431.c7
[33]
Robinet P, Ritchey B, Smith JD (2013) Physiological difference in autophagic flux in macrophages from 2 mouse strains regulates cholesterol ester metabolism. Arterioscler Thromb Vasc Biol 33: 903–910. doi: 10.1161/atvbaha.112.301041
[34]
Ouimet M, Franklin V, Mak E, Liao X, Tabas I, et al. (2011) Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab 13: 655–667. doi: 10.1016/j.cmet.2011.03.023
[35]
Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, et al. (2005) Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115: 1333–1342. doi: 10.1172/jci200523915
[36]
Vrins CL, Ottenhoff R, van den Oever K, de Waart DR, Kruyt JK, et al. (2012) Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. J Lipid Res 53: 2017–2023. doi: 10.1194/jlr.m022194
[37]
Le May C, Berger JM, Lespine A, Pillot B, Prieur X, et al. (2013) Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1. Arterioscler Thromb Vasc Biol.
[38]
Jiang XC, Beyer TP, Li Z, Liu J, Quan W, et al. (2003) Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression. J Biol Chem 278: 49072–49078. doi: 10.1074/jbc.m304274200
[39]
van der Veen JN, van Dijk TH, Vrins CL, van Meer H, Havinga R, et al. (2009) Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem 284: 19211–19219. doi: 10.1074/jbc.m109.014860
